Avenue Therapeutics Inc (NASDAQ:ATXI) Short Interest Up 37.1% in November

Share on StockTwits

Avenue Therapeutics Inc (NASDAQ:ATXI) saw a significant increase in short interest during the month of November. As of November 29th, there was short interest totalling 20,700 shares, an increase of 37.1% from the November 14th total of 15,100 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average trading volume of 19,700 shares, the days-to-cover ratio is currently 1.1 days.

NASDAQ:ATXI traded up $0.82 on Thursday, reaching $7.63. The company’s stock had a trading volume of 3,000 shares, compared to its average volume of 16,142. Avenue Therapeutics has a 1-year low of $4.13 and a 1-year high of $7.98. The firm has a market cap of $102.13 million, a PE ratio of -3.64 and a beta of -0.43. The business’s 50-day moving average price is $5.84 and its two-hundred day moving average price is $5.89.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.18. As a group, equities research analysts forecast that Avenue Therapeutics will post -1.66 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. National Asset Management Inc. boosted its position in shares of Avenue Therapeutics by 9.3% during the second quarter. National Asset Management Inc. now owns 64,750 shares of the company’s stock worth $408,000 after buying an additional 5,500 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Avenue Therapeutics during the third quarter worth about $76,000. Finally, BlackRock Inc. boosted its position in shares of Avenue Therapeutics by 135.7% during the second quarter. BlackRock Inc. now owns 39,933 shares of the company’s stock worth $251,000 after buying an additional 22,994 shares during the period. 8.72% of the stock is owned by institutional investors.

Separately, ValuEngine upgraded Avenue Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 15th.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Featured Story: Buy Rating

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abbott Laboratories  Updates Q1 2020
Pre-Market Earnings Guidance
Abbott Laboratories Updates Q1 2020 Pre-Market Earnings Guidance
Express  Issues Q4 2019
Pre-Market Earnings Guidance
Express Issues Q4 2019 Pre-Market Earnings Guidance
Applied Industrial Technologies  Releases FY20 Earnings Guidance
Applied Industrial Technologies Releases FY20 Earnings Guidance
Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.


© 2006-2020 Ticker Report